|
|
Blood, 1 September 2006, Vol. 108, No. 5, pp. 1668-1676.
Prepublished online as a Blood First Edition Paper on April 27, 2006; DOI 10.1182/blood-2006-04-015586.
Previous Article | Next Article 
Submitted April 11, 2006
Accepted April 16, 2006
Constitutive activation of Akt contributes to the
pathogenesis and survival of mantle cell lymphoma
Martina Rudelius, Stefania Pittaluga, Satoshi Nishizuka, Trinh H-T Pham, Falko Fend, Elaine S Jaffe, Leticia Quintanilla-Martinez, and Mark Raffeld*
Hematopathology Section, Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD
Molecular Therapeutics Program, National Cancer Institute, NIH, Bethesda, MD
Institute of Pathology Technical University of Munich, Munich, Germany
GSF-National Research Center for Health and Environment, Neuherberg, Germany
* Corresponding author; email: mraff{at}box-m.nih.gov.
To determine whether the PI3K/Akt signaling pathway is involved in the pathogenesis of mantle cell lymphoma (MCL), we investigated the phosphorylation status of Akt and multiple downstream targets in primary MCL cases and cell lines. Akt was phosphorylated in 12/12 aggressive blastoid MCL variants and in 4/4 MCL cell lines. In contrast, phosphorylated Akt was present in only 5/16 typical MCL, 3 at comparable levels to the blastoid cases, and 2 at low levels. The presence of p-Akt was accompanied by the phosphorylation of p27kip1, FRKHL-1, MDM2, Bad, mTOR, and p70S6K. Inhibition of the PI3K/Akt pathway in the MCL cell lines abrogated or reduced the phosphorylation of Akt, p27kip1, FRKHL-1, MDM2, Bad, mTOR, GSK-3 , I B, and led to cell cycle arrest and apoptosis. Six MCL cases (5 with activated Akt and one with inactive Akt), and 3/4 cell lines showed loss of PTEN expression. PI3KCA mutations were not detected. We conclude that constitutive activation of the PI3K/Akt pathway contributes to the pathogenesis of MCL, and preferentially occurs in blastoid variants. One possible mechanism of activation is loss of PTEN expression. These data suggest that PI3K/Akt inhibitors may be effective in the treatment of Akt-activated MCL.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
AKTion on mantle cell lymphoma
- Michael R. Gold
Blood 2006 108: 1425-1426.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
A. Psyrri, S. Papageorgiou, E. Liakata, A. Scorilas, D. Rontogianni, C. K. Kontos, P. Argyriou, D. Pectasides, N. Harhalakis, V. Pappa, et al.
Phosphatidylinositol 3'-Kinase Catalytic Subunit {alpha} Gene Amplification Contributes to the Pathogenesis of Mantle Cell Lymphoma
Clin. Cancer Res.,
September 15, 2009;
15(18):
5724 - 5732.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Levy, J. A. Kahana, and R. Kumar
AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines
Blood,
February 19, 2009;
113(8):
1723 - 1729.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Tabe, D. Sebasigari, L. Jin, M. Rudelius, T. Davies-Hill, K. Miyake, T. Miida, S. Pittaluga, and M. Raffeld
MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma
Clin. Cancer Res.,
February 1, 2009;
15(3):
933 - 942.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Gelebart, M. Anand, H. Armanious, A. C. Peters, J. Dien Bard, H. M. Amin, and R. Lai
Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma
Blood,
December 15, 2008;
112(13):
5171 - 5179.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Sun, X. Zhang, S. Talathi, and B. S. Cummings
Inhibition of Ca2+-Independent Phospholipase A2 Decreases Prostate Cancer Cell Growth by p53-Dependent and Independent Mechanisms
J. Pharmacol. Exp. Ther.,
July 1, 2008;
326(1):
59 - 68.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Dal Col, P. Zancai, L. Terrin, M. Guidoboni, M. Ponzoni, A. Pavan, M. Spina, S. Bergamin, S. Rizzo, U. Tirelli, et al.
Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
Blood,
May 15, 2008;
111(10):
5142 - 5151.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|